!!!!!! MIT ANSAGE: INTROGEN (INGN) +40% !!!!!!! - 500 Beiträge pro Seite

[chirint]

Siehe frühere postings !!!

[zet100]

RESPEKT!


Nur schade das Du Alleinunterhalter bist!

[BrauchGeld]

Läuft wirklich gut die Aktie.Mal sehen wie weit die geht.

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/03/2003 (13:31 ET) INGN Study Shows 90% Response; Treated w/ Advexin - Knobias



06/03/2003 (13:00 ET) Phase 2 Breast Cancer Study Shows Clinical Responses in 90 Percent of Patients Treated With Introgen`s Advexin Therapy - PR Newswire



06/03/2003 (11:51 ET) VOLUME(+): INGN Volume 21% > 20-adsv, Stock +10.45% - Knobias



06/03/2003 (09:46 ET) 52W HIGH: New 52-Wk High for INGN @ $4.150 up11.80% - Knobias



06/02/2003 (15:00 ET) MOVER(+): INGN Reports Positive Data for Advexin Study - Knobias



06/02/2003 (14:30 ET) Introgen`s Advexin Therapy Halts Tumor Growth in Advanced Esophageal Cancer Patients - PR Newswire



06/02/2003 (12:46 ET) 52W HIGH: New 52-Wk High for INGN @ $3.710 up10.75% - Knobias



06/02/2003 (12:39 ET) MOVER(+): INGN Reports Positive Results for Advexin - Knobias



06/02/2003 (12:30 ET) Introgen`s Intrabronchial Advexin Therapy Demonstrates Safety and Clinical Activity in Bronchoalveolar Lung Cancer - PR Newswire



06/02/2003 (11:22 ET) VOLUME(-): INGN Volume 13% > 20-adsv, Stock -0.30% - Knobias



05/28/2003 (13:33 ET) INGN: Short Interest DN 66.5% to 47.0K in May 2003 - Knobias



05/27/2003 (14:22 ET) VOLUME(+): INGN Volume 40% > 20-adsv, Stock +9.09% - Knobias



05/15/2003 (15:20 ET) New 10-Q just released for INGN - Edgar



05/13/2003 (17:26 ET) New 8-K/A just released for INGN - Edgar



05/13/2003 (13:32 ET) Introgen Therapeutics Reports First Quarter 2003 Results - PR Newswire



05/13/2003 (13:30 ET) Introgen Therapeutics Reports First Quarter 2003 Results - PR Newswire



05/13/2003 (11:57 ET) ERN(-): INGN/Q1 (25c) vs (37c); Misses Q Est; No Guidance - Knobias



05/13/2003 (11:41 ET) New 8-K just released for INGN - Edgar



05/12/2003 (16:02 ET) Introgen Therapeutics Announces First Quarter 2003 Earnings Conference Call - Business Wire



05/08/2003 (15:34 ET) DEFR 14A: INGN Vote; Elect Directors; Ratify Auditor - Knobias



05/08/2003 (15:27 ET) New DEFR14A just released for INGN - Edgar


JS200

[js200]

Könnte weit laufen!!!!!!!!!!

http://www.investtech.com/nasdaq/ana/ingn.htm

JS200

[meislo]

Zur Zeit läuft alles was bei Krebsbehandlung erfolgreich ist...Wie lange noch ? Warscheinlich aber ein neuer Trend
und den gilt es mitzugehen.Auf denm Gebiet der Kredsbehandlung wird es wohl in den nächsten Jahren einen wirklichen Durchbruch geben!!!!!

Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup







Dow Jones Business News
Phase 2 Breast Cancer Study Shows Clinical Responses In 90 % Of Patients Treated With Introgen`s Advexin Therapy>INGN
Tuesday June 3, 2:12 pm ET


CHICAGO -(Dow Jones)- Introgen Therapeutics Inc.`s Advexin can be safely combined with a standard two-drug chemotherapy regimen, and 90% of patients with locally advanced breast cancer had complete or partial responses to the combination, according to preliminary data from a Phase II study.
ADVERTISEMENT





Study patients experienced few side effects, which mainly consisted of irritation at the injection site that cleared up in a few days.

In a press release Tuesday, the company said the treatment could eventually be applied to patients with every stage of breast cancer, as none of the patients in the study saw their illness progress.

The study is evaluating the administration of Advexin in combination with systemic doses of Aventis SA`s Taxotere and Pharmacia Corp.`s (PFE) Adriamycin, for four months prior to cancer-removal surgery. The surgery was followed by postoperative therapy.

The primary endpoint of the study was the complete pathological remission rate at the time of surgery. Pathological examination revealed only scattered residual tumor cells, the company said.

Introgen said Advexin selectively kills cancer cells with very high concentrations of p53 protein while not harming the surrounding normal cells. P53, a normal cell constituent, suppresses tumors with a "halt" signal that stops mutated cells from growing, and either causes the cell to repair itself or die. The P53 gene is mutated in about half the cases of aggressive breast cancer so that production of the protein isn`t enough to control cell growth. Even if the p53 gene is still normal, its function can be disrupted in other ways, such as rapid decay.

Earlier Tuesday, Introgen reported a phase I/II study in which Advexin seemed to slow the growth of esophageal tumors and was well-tolerated by patients in the study. Introgen is also conducting two Phase III studies of Advexin as a treatment for advanced head and neck cancer and a Phase I/II study with nonsmall-cell lung cancer patients.

At about 3 p.m., Introgen`s shares traded at $5.03, up $1.32, or 35.5%, on Nasdaq volume of 821,300 shares, more than nine times the average daily volume. Earlier in the day, the stock set a new 52-week high of $5.24, beating the previous high of $4.11 set Monday.

Company Web site: http://www.introgen.com